Arbutus Biopharma Corp (NASDAQ:ABUS) – Equities researchers at William Blair issued their Q1 2017 earnings estimates for shares of Arbutus Biopharma Corp in a note issued to investors on Wednesday, according to Zacks Investment Research. William Blair analyst Y. Xu anticipates that the biopharmaceutical company will post earnings per share of ($0.25) for the quarter. William Blair also issued estimates for Arbutus Biopharma Corp’s Q2 2017 earnings at ($0.39) EPS, Q3 2017 earnings at ($0.39) EPS, Q4 2017 earnings at ($0.39) EPS, FY2017 earnings at ($1.42) EPS, FY2018 earnings at ($1.63) EPS and FY2019 earnings at ($1.76) EPS.
ABUS has been the subject of several other reports. Zacks Investment Research upgraded Arbutus Biopharma Corp from a “sell” rating to a “hold” rating in a research report on Friday, February 17th. Wedbush reiterated an “outperform” rating and issued a $10.00 target price on shares of Arbutus Biopharma Corp in a research report on Tuesday, January 31st. Bloom Burton upgraded Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a research report on Monday, January 9th. Finally, Chardan Capital upgraded Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $3.00 to $6.00 in a research report on Tuesday, April 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $6.25.
COPYRIGHT VIOLATION NOTICE: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://transcriptdaily.com/2017/04/22/arbutus-biopharma-corp-to-post-q1-2017-earnings-of-0-25-per-share-william-blair-forecasts-abus.html.
Institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its position in Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock valued at $2,964,000 after buying an additional 50,768 shares during the period. Baker BROS. Advisors LP acquired a new position in Arbutus Biopharma Corp during the third quarter valued at $621,000. K2 Principal Fund L.P. raised its position in Arbutus Biopharma Corp by 69.3% in the third quarter. K2 Principal Fund L.P. now owns 107,620 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 44,070 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its position in Arbutus Biopharma Corp by 1,058,889.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,294,945 shares of the biopharmaceutical company’s stock valued at $12,972,000 after buying an additional 5,294,445 shares during the period. Finally, Oxford Asset Management acquired a new position in Arbutus Biopharma Corp during the fourth quarter valued at $392,000. Institutional investors own 61.24% of the company’s stock.
Arbutus Biopharma Corp Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get a free copy of the Zacks research report on Arbutus Biopharma Corp (ABUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
